Ionis Pharmaceuticals, the largest holding company in BB Biotech’s portfolio, has been in the news. The American biotech company today presented the results of a phase 2b study of fesomersene. The drug candidate is being developed as a factor XI production-reducing drug to prevent thrombosis – previously in collaboration with license partner Bayer, which also conducted the study. The study involved , hemodialysis patients with end-stage renal disease. „In the study, Fesomersen achieved its primary endpoint of major bleeding and clinically significant non-major bleeding (CRNM) over a 2 -week treatment period,” reports Ionis Pharma. Other learning objectives were also met. Fesomersen also demonstrated favorable safety and tolerability over a 8-week treatment period, according to the biotech company.
Ionis Pharma: New data on Fesomersen – a new partner is to come after Bayer
![](https://www.how-to-start-investing.com/wp-content/uploads/2022/07/ftx-token-symbol-trade-with-cryptocurrency-digital-virtual-money-banking-with-mobile-phone-concept-business-workspace-table-top-view-photo-scaled.jpg)